Laserfiche WebLink
One of the of the highest profile life science <br />deals Of 2018 was made in a Tri -Valley company. <br />In October 2018, sox Genomics raised a $125 <br />million Series D round at a $1.3 billion valuation <br />with investments from Meritech Capital Partners, <br />Wells Fargo, SoftBank and others. The company <br />generates over $loo million in annual revenue <br />developing both software and hardware <br />tools for single -cell genomics researchers. Its <br />product suite includes Laboratory tools for gene <br />expression, immune profiling, clonal evolution, <br />genome sequencing, exome sequencing, diploid <br />genome assembly and more. "As a company, <br />we've seen tremendous growth and expansion <br />in the last year," said Serge Saxonov, CEO and <br />Co -Founder. "We've released new products, <br />announced new facilities, and welcomed <br />two incredible companies to the sox team. <br />Today's funding announcement will allow us <br />to continue with this momentum into 2019 <br />as we scale sox to become a company that <br />impacts billions of lives around the world." <br />For sox Genomics, being in the Tri -Valley <br />works. "Pleasanton is the sweet spot where <br />you get the talent from all across the Bay <br />Area and rents aren't quite as expensive as <br />San Francisco." The company is currently <br />expanding from a 40,000 square foot facility <br />to one with over 150,000 square feet, and <br />plans to hire 200 additional employees over <br />the upcoming months. With valuations more <br />than tripling over the past three years and <br />revenue accelerating, it's possible that we <br />could see the company go public later in 2019. <br />sox Genomics Capital History <br />Oct. 2012 S4 7M Seed <br />May 2013 $1.4M Debt <br />Oct 2013 $22.4M Series A <br />Dec. 2014 $55 5M Series B <br />Mar. 2016 $75M Series C <br />Oct. 2o18 $35M Series D1 <br />Jan. 2019 $125M Series D <br />24 <br />